Business
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th. Mr. Barad's talk will focus on the pharmaceutical development of synthetic cannabinoid-based drug candidates for colorectal cancer and other cancers designated for FDA regulatory review.\n\n \n \n \n \n \n \n\n \nEyal Barad, Cannabics Pharmaceuticals Co-Founder and CEO said: \"We are proud to have been selected to present at Edison's Open Forum Conference and share our perspective on synthetic cannabinoid drug development and on the challenges, opportunities and trends we see in the industry.\"\nTo access the Forum and the presentation please register at the following link:\n https://www.edisongroup.com/cbd-2021/ \nRead more:\nRecent expansion of Company's IP Portfolio with filing of 2 new Provisional Patents; Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.). Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.\nAbout Cannabics P...